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Background: Triple negative breast cancer (TNBC) and often basal-like cancers are defined as negative for estrogen
receptor, progesterone receptor and Her2 gene expression. Over the past few years an incredible amount of data
has been generated defining the molecular characteristics of both cancers. The aim of these studies is to better
understand the cancers and identify genes and molecular pathways that might be useful as targeted therapies. In
an attempt to contribute to the understanding of basal-like/TNBC, we examined the Gene Expression Omnibus
(GEO) public datasets in search of genes that might define basal-like/TNBC. The Il32 gene was identified as a
candidate.
Findings: Analysis of several GEO datasets showed differential expression of IL32 in patient samples previously
designated as basal and/or TNBC compared to normal and luminal breast samples. As validation of the GEO results,
RNA and protein expression levels were examined using MCF7 and MDA MB231 cell lines and tissue microarrays
(TMAs). IL32 gene expression levels were higher in MDA MB231 compared to MCF7. Analysis of TMAs showed 42%
of TNBC tissues and 25% of the non-TNBC were positive for IL32, while non-malignant patient samples and all but
one hyperplastic tissue sample demonstrated lower levels of IL32 protein expression.
Conclusion: Data obtained from several publically available GEO datasets showed overexpression of IL32 gene in
basal-like/TNBC samples compared to normal and luminal samples. In support of these data, analysis of TMA clinical
samples demonstrated a particular pattern of IL32 differential expression. Considered together, these data suggest
IL32 is a candidate suitable for further study.
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TNBC are defined as negative for expression of three
genes, estrogen receptor (ESR), progesterone receptor
(PR) and Her2 gene, and account for 15-20% of breast
cancer types. They represent a sub-population of breast
cancers that demonstrate aggressive behavior, overall
poorer prognosis, and higher grade and risk of recurrence
compared to other types of breast cancers [1]. Basal-like
breast cancers are also aggressive, with overall poorer
prognosis, negative for ESR/PR/Her2 and positive for
HER1+ and cytokeratin 5/6+ [2,3]. Often times investiga-
tors refer to basal-like and TNBC as synonymous type of* Correspondence: playeran@tsu.edu
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unless otherwise stated.cancer. Even though basal-like cancers and TNBC are
similar, data show that on a molecular level, they are
somewhat different. Prat et al. [4] performed microarray
analyses of 412 TNBC and 473 basal-like samples and
showed that 21.4% of the TNBC were non-basal-like, and
31.5% of the basal-like tumors were non-TNBC. In another
study Lehmann et al. [5] identified seven subtypes within
TNBC samples, including basal1, basal2, immunomodula-
tory, mesenchymal, mesenchymal stem-like, luminal andro-
gen receptor and an unstable type. Rody et al. [6] analyzed
samples that were previously characterized as TNBC
and found that 73% of TNBC demonstrated a basal-like
molecular signature while the remaining samples were
not basal-like. Collectively, these data are evidence that
samples characterized as TNBC consist of a subpopulation
of samples with diverse molecular characteristics, thosetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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displaying characteristics similar to other breast sub-
types. These studies emphasize the differences between
TNBC and basal-like cancers, but overwhelmingly the
data also show the similarities between the cancers and
reveal the molecular complexities of breast cancers in
general.
From a therapeutic standpoint, it is critically important
that we understand TNBC and basal-like cancers. While
effective targeted gene therapies exist for breast cancers
displaying positive receptor status, fewer treatment
options exist for patients displaying negative receptor
status. Breast cancers displaying positive receptor status
are effectively treated with hormonal therapies that target
their receptor genes and Her2. Effective molecular targets
related to basal-like/TNBC cancers have not been
identified. Effective therapeutic targets can only come
from understanding the biology of the disease and
identifying reliable genetic signatures to study for their
potential use in treating patients. The development of
new, specific targeted therapies will be of significant
benefit to patients unresponsive to current therapies. In
an attempt to contribute to these studies, we examined
publically available GEO datasets in search of novel genes
that might be differentially expressed in breast cancers.
Taking into account the similarity between the two can-
cers, we specifically chose to analyze public datasets that
were previously characterized as basal-like/TNBC, luminal
and non-tumor in search of genes that were differentially
expressed in both the basal-like and TNBC subtypes
compared to the other subtypes. For our initial selection,
datasets were limited to those with online data-analyses
tools and because of the similarity between basal-like and
TNBC, datasets were selected based on search filters using
the terms “basal breast cancer”. From our search, we iden-
tified datasets containing patient samples and cell lines in
which the receptor status was known. The datasets were
analyzed and the candidate genes were selected. The IL32
gene was selected for further study because it was
differentially expressed in basal-like clinical samples and
TNBC cell lines, compared to samples defined by the
other subtypes.
The IL32 gene was initially identified by Kim et al. [7]
following overexpression of IL18 receptor-beta in A549
human lung adenocarcinoma cells. The IL32 gene is a
pro-inflammatory cytokine produced by immune, endo-
thelial and epithelial cell types and is processed as alterna-
tive splice variants. Limited data exist describing the IL32
cytokine in cancers; however there is evidence the gene is
suppressive in some cancers and facilitative in other
cancers. IL32 was shown to suppress hepatocellular
cancers, melanoma and colon cancers [8]. Oppositely,
overexpression of IL32 has been shown to be an independ-
ent prognostic marker for gastric cancer [9,10].As part of this study, we observed overexpression of
IL32 gene in a subgroup of the basal-like/TNBC samples
compared to normal and luminal samples retrieved from
GEO. We then experimentally validated IL32 RNA and
protein expression levels in cell lines and tissue microar-
rays (TMAs) in which the receptor status was known; a
similar pattern of differential expression was observed.
To our knowledge this is the first study demonstrating a
differential pattern of IL32 expression in breast tissues.
Methods
Cell culture and tissue microarray samples
MCF7 cells were used to represent non-basal-like (receptor
positive) samples and MDA MB231 cell line was used to
represent TNBC/basal-like samples. Cell lines were pur-
chased from American Type Culture Collection (ATCC;
Manassas VA). MCF7 and MDA-MB-231 cell lines were
grown in DMEM/F12 (Gibco/Invitrogen; Carlsbad, CA)
culture media, supplemented with 10% fetal bovine serum
and an antimycotic solution. All of the cells were main-
tained in a 37°C incubator with 5% CO2 in a humidified
environment. For analysis of patient samples, paraffin-
embedded tissue microarray (TMA; catalog # BRC1506
and BRC1021) samples were purchased from Pantomics
Incorporated (Richmond CA). TMAs included different
breast tissues representing an assortment of clinical diag-
noses. Documents supplied by the company state that
they are dedicated to the ethical procurement of tissues
from human donors and the ethical treatment of animals,
and all tissues are collected under strict guidelines and
consent. TMA samples were supplied with age, pathology,
grade, stage, ESR, PR and Her2 status. The ESR/PR/Her2
receptor status of each TMA was determined by immuno-
histochemistry (IHC) staining and scored by pathologists
affiliated with the company. Scores ranged from 0–3;
samples designated as “0” for all three receptors were
designated as TNBC, and values higher than zero were
considered positive for one or more receptors. Tissue
samples that were positive for 1 or more receptor were
considered non-TNBC in this study.
Data analysis
The breast cancer datasets were selected from GEO [11].
Datasets were initially selected using the search terms
“Affymetrix/basal/breast cancer”. One hundred thirty seven
GEO datasets appeared using these terms. We examined
each dataset and screened for (a) samples processed using
the Affymetrix U133 microarray platform (Santa Clara CA;
[12-14] and (b) human/breast cancer samples that were not
genetically manipulated or previously treated with drugs.
Eight datasets were selected but 3 were excluded because
they either contained too few breast samples or in the
case of one, the dataset contained only TNBC samples. The
five datasets included GDS2250, GDS1329, GSE34211,
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GDS2250 and GSE7904 were separate studies originat-
ing from the same clinical sample dataset. GDS2250
and GDS1329 datasets included clinical patient sam-
ples and GSE34211 and GSE12777 datasets included
studies using cell line samples.
For our initial analyses, preference was given to datasets
designated by GEO as “curated”, because the curated data-
sets included online tools that allowed for T-test compari-
sons, gene cluster displays, an up-down selection function
to display differentially expressed genes, normalized indi-
vidual gene-expression-profile charts and neighbor-analyses
functions. The GDS2250 and GDS1329 are curated data-
sets. Since we were able to use the online analysis tools
available for the curated samples, GDS2250 and the
GDS1329 datasets were processed first. The remaining
2 datasets were used to assess gene expression levels in
datasets containing basal-like/TNBC samples.
The GDS2250 and GDS1329 datasets contained differ-
ent types of samples. Samples in the GDS2250 dataset
were previously identified as normal, non-basal-like and
basal-like breast cancer types; samples in the GDS1329
dataset were previously identified as apocrine, basal and
luminal type breast cancers. Throughout our analyses, we
maintained the nomenclature assigned to the dataset; for
example if samples were designated non-basal-like (as in
GDS2250), we continued that designation throughout our
study. Samples in the GDS2250 dataset were designated
as normal, non-basal-like and basal-like, as a result, our
approach was to focus on genes differentially expressed
in the basal-like samples compared to normal and non-
basal-like. Initially the goal of our studies was to identify
genes differentially expressed in TNBC, however, recog-
nizing the relationship between basal-like and TNBC, we
focused on identifying samples related to both subtypes.
The GDS2250 and GDS1329 datasets were analyzed
separately in search of differentially expressed genes, with
GDS2250 analyzed first. The GDS2250 datasets were
examined using GEO’s “Data Analysis tool” and the linear
relationship was established using Pearson distance correl-
ation. Hierarchical cluster and gene expression patterns
were examined and particular gene clusters were selected.
Individual gene expression profiles related to the dataset
were validated by searching the “GEO gene-expression-
profile charts” using keywords “GDS2250 and the gene-
of-interest”. GDS1329 was examined following the same
approach. Gene-expression-profile charts available in GEO
were used to validate the expression patterns. Differentially
expressed genes common between GDS2250 and GDS1329
were selected as possible gene candidates. Based on the ini-
tial selection methods, candidates were defined as basal-like
genetic signatures. IL32 and several other genes were
identified as differentially expressed following analysis of
the GDS2250 and GDS1329 datasets.Candidate genes were further examined for expression
in the GSE34211 and GSE12777 datasets. The GSE34211
and GSE12777 datasets contained cell lines characterized
as luminal and basal-like. The receptor status of the cell
lines was known which allowed for analysis of IL32 in
TNBC samples. Gene-expression-profile charts were not
available at GEO for the two datasets, however normalized
gene expression values were available. IL32 was finally
selected because the gene showed differential expression
in GDS2250, GDS1329, in several TNBC cell lines exam-
ined as part of the GSE34211 study and in the GSE12777
dataset. For direct comparison across datasets, the IL32
Affymetrix 203828_s_at probe-set was analyzed for all of
the samples examined.
Once the IL32 gene was identified, the gene expression
values corresponding to the Affymetrix 203828_s_at
probe-set were downloaded into Excel. Gene expression
values related to individual datasets were listed as either
normalized signal intensities or log2 values. For the
datasets in which IL32 was listed as log2 values, for
comparison across the four different datasets, the values
were converted back to the normalized signal intensity
value using the Excel antilog function.
Data show that IL32 gene is processed as alternative
slice variants. The sequences corresponding to the IL32
splice variants were retrieved from Ensembl [15], NCBI
Reference Sequences (RefSeq) [16] and GeneCards [17],
and the gene alignments were performed using the
Multi-Align™ program [18].
cDNA generation and real-time PCR validation
For each sample, one microgram of total RNA was used to
generate cDNA using the iScript kit (BioRad Life Science;
Hercules, CA). The cDNA samples were diluted to
10 ng/ul with RNAse free water and stored at −20°C
until ready for PCR. The gene primer-sets were designed
using Primer3 [19]. Primer-sets were synthesized by
IDTDNA (Coralville, IA). The IL32 gene exists as spliced
transcript variants. We chose to use IL32 RefSeqs as our
resource for the IL32 gene. We identified eight reference
sequence (RefSeq) transcript variants deposited at NCBI
[16] and GeneCards [17]. The sequences were retrieved
and analyzed using tools available at the University of
California at Santa Cruz (UCSC) Genome Browser [20].
The final set of primers used for the study was designed
to accomplish two goals. To begin, IL32 primers were
designed to recognize as many of the RefSeqs as possible
(Additional file 1: Table S1). Then, primers were designed
to recognize the same antigenic region as recognized by
the antibody used for our study, allowing for direct
comparisons between results observed for the RNA and
protein studies. The experimental approach related to
the protein studies is described below. Related to the
RNA studies, several different primer-sets were tested,
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forward primer sequence AGCTGGAGGACGACTTC
AAA and the reverse primer sequence CCTGGAACC
ATCTCATGACC, which generated a 207 base pair (bp)
amplicon. The Mitochondrial ribosomal protein L19
(MRPL19) gene was used as the endogenous control
which included a forward primer sequence of AAGC
GTCGAAAAGGTCTTGA and reverse sequence of
GCTCAGGTTCCATGCTCATT which generated a 306 bp
amplicon. The specificity of the primer-sets was validated
using the web-based in-silico PCR program available as a
part of the UCSC Genome Browser [20]. PCR reactions
were performed using the Bio-Rad PCR amplification
system.
Western blotting and immunohistochemistry
Cluster of differentiation 1 (CD31) antibody (ab133191)
was purchased from Abcam (Cambridge, MA), and the
IL32 antibody (NBP-1 82560) was purchased from Novus
Biologicals (Littleton, CO). The IL32 antibody recognizes
the FPKVLSDDMKKLKARMHQAIERFYDKMQNAESG
RGQVMSSLAELEDDFKEGYLETVAAYYEEQHPELTPLL
EKERDGLRCRTMA sequence, corresponding to IL32
specific protein and transcript sequences [21]. We found
that investigators involved in generating the IL32 antibody
used Ensembl database as their source for the IL32
sequences instead of NCBI. The IL32 antibody supplied
by Novus Biologicals has been used to examine an as-
sortment of different tissues and diseases as part of the
Human Protein Atlas project [22]. Related to their
study, the Protein Atlas project provides (a) a list of the
IL32 variant sequences that match the antigen sequence
and (b) a direct link for convenient retrieval of the
matching variant sequences, available through the Ensembl
database. The protein and transcript variant identifications
for the sequences that match the antigenic region (i.e.,
epitope) are listed in Additional file 2: Table S2 [15,21].
Only sequences that match 100% of the epitope are
listed in the table.
Our goal was to design a PCR primer-set to detect all
or most of the sequences recognized by the commercial
IL32 antibody and the IL32 RefSeqs. Once accomplished,
the Multialign™ program was used to determine the similar-
ity between the sequences. In summary, the Multialign™
comparisons demonstrate the similarity between (a) the
transcripts corresponding to the IL32 protein sequences
used to generate the antibody (b) the RefSeq transcripts
corresponding to the IL32 sequences used to generate the
PCR amplicon and (c) the sequence corresponding to our
207 bp IL32 PCR amplicon (Additional file 3: Figure S1).
For this particular alignment, the approximate location of
the amplicon is between nucleotides 576–783. Results show
that our PCR primers recognize most of the RefSeqs and
transcripts defined as matching to the protein epitope.The same antibody was used for Western blotting and
IHC studies. Western blotting was performed as suggested
by Novus Biologicals. As control for the western blotting,
an IL32 protein lysate (NBL1-11952) was purchased
from Novus Biologicals. The lysate was generated from
HEK293T cells that were transfected with a plasmid
containing the IL32 gene insert (NM_004221). The empty
vector was supplied with the IL32 lysate, and served as the
negative control for IL32 expression. Positive and negative
IL32 controls were loaded at equivalent concentrations
and only exposed long enough for detection of IL32
positive control. Actin gene was used as the endogenous
control gene. IHC was performed as recommended by
Vector Labs (Burlingame, CA).
TMA samples were deparaffinized and antigen retrieval
performed by heating the TMAs at 98°F degrees for
45 minutes in 0.01 M sodium citrate buffer, pH 6.0. The
TMAs were developed using DAB Peroxidase Substrate
Kit,
3, 3’-diaminobenzidine (VectorLabs; Burlingame CA),
counterstained, cover-slipped and examined. The TMAs
were scored based on ranking the IHC signal intensities
from 0-5+; 0 represented no-detectable signal while
5+ represented an intense signal detected on either
the entire TMA core or at least 25% of an individual
core. Only TMA cores that demonstrated at least a
“3+” signal for the CD31 control, minus background
were included in the analyses. The CD31 antibody
recognizes cell adhesion molecules predominantly associ-
ated with endothelial cells. As a result, positive CD31 signal
in regions other than blood vessels was considered back-
ground staining. Analysis of the IHC results was performed
using the Nikon Eclipse™ microscope (Nikon Instruments
Inc., Melville, NY).
Results
Identification and assessment of IL32 transcript(s)
differentially expressed in basal-like / TNBC compared to
non-basal-like samples
Selection of IL32 based on gene expression in publically
available GEO datasets
It is clear from recent reports that on a molecular level,
breast cancers are incredibly complex. Although defined
by different subtypes, our goal was to identify genes differ-
entially expressed in cancerous breast tissues defined as
both basal-like and TNBC. The genes were initially
selected based on analyses of the publically available
GEO datasets. Table 1 lists the GEO datasets used for
our study. Four different datasets were ultimately chosen
using the criteria listed in the Methods section. Two of
the datasets included clinical patient samples and two
others included cell line samples. The references describ-
ing the original scientific studies are given in the table.
Throughout this study we maintained the nomenclature
Table 1 Summary of the publically available GEO datasets used in the study




GDS2250/GSE7904 Patients Normal/non-basal-like/basal n = 47 Richardson AL, Wang ZC, De Nicolo A, Lu X et al.
X chromosomal abnormalities in basal-like human
breast cancer. Cancer Cell 2006 Feb;9(2):121–32.
GDS1329 Patients Apocrine/basal/luminal n = 49 Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M
et al. Identification of molecular apocrine breast
tumours by microarray analysis. Oncogene 2005
Jul 7;24(29):4660–71.
GSE34211 Cell lines Luminal/basal n = 35 Hook KE, Garza SJ, Lira ME, Ching KA et al. An
integrated genomic approach to identify predictive
biomarkers of response to the aurora kinase
inhibitor PF-03814735. Mol Cancer Ther 2012
Mar;11(3):710-9
GSE12777 Cell lines Luminal/basal n = 49 Hoeflich KP, O’Brien C, Boyd Z, Cavet G et al. In vivo
antitumor activity of MEK and phosphatidylinositol
3-kinase inhibitors in basal-like breast cancer models.
Clin Cancer Res 2009 Jul 15; 15(14):4649–64.
The datasets were retrieved from GEO based on search terms. The types of samples used for the particular study, the number of samples processed and the
reference for the original publications are listed. The characteristics and subtype designations were assigned by the original investigators.
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nated ‘non-basal-like’ as opposed to luminal subtype, sam-
ples are designated as non-basal when referenced in this
report.
We first selected genes differentially expressed in
basal-like patient samples, finally selecting genes dem-
onstrating concordant expression in TNBC cell lines.
The “data analysis tools” available on GEO were used
to analyze the GDS2250 breast cancer dataset and IL32
was found differentially expressed in the basal-like patient
samples. GDS1329 was also examined for IL32 gene
expression levels and found differentially expressed in the
basal-like patient samples. There were substantial ranges
in the IL32 gene expression levels between individual
samples, still the mean-values for the basal-like samples
were higher than values observed for the other subtypes
in both GDS2250 and GDS1329 (Figure 1a and b). As
validation of IL32 levels in samples of known receptor
status, the GSE34211 dataset was examined. The dataset
included cell line samples with positive receptors and
TNBC (Figure 1c), grouped as luminal and basal-like.
Only the basal-like/TNBC samples demonstrated high
IL32 expression. Compared to all other samples in the
dataset, at least 7 of the 18 basal-like/TNBC samples
expressed high levels of IL32; MCF10A and MCF12A
(non-cancer) triple negative cell lines were included in
the 11 samples that expressed low levels of IL32. The
GSE12777 dataset also showed higher IL32 levels in
basal compared to luminal cell lines (Figure 1d). Eleven
basal-like/TNBC cell lines were common between the
GSE34211 and GSE12777 datasets. Of these cell lines,
five (i.e., HCC1569, HCC1143, MDA MB436, Cal851
and Hs578T) displayed overexpression of IL32 in bothGSE34211 and GSE12777 datasets. The relationship be-
tween these five cell lines is not obviously apparent.
In GSE34211, low levels of IL32 were observed in
MDA MB231, but normalized signal levels exceeded
MCF7; MDA MB231 was 10 compared to MCF7 which
was 4. In GSE12777, MDA MB231 was clearly overex-
pressed compared to luminal samples. Overall, analysis of
the GEO public datasets showed overexpression of IL32
in patient samples and cell lines previously characterized
as either basal-like or TNBC. All of the basal-like/TNBC
samples did not show overexpression of IL32, but of the
samples expressing high levels, all were basal-like/TNBC.
Experimental assessment of IL32 gene expression levels
IL32 gene expression in the GEO samples was based on
analysis of the Affymetrix 203826_s_at probeset. As val-
idation of IL32 in GEO results, initially primer-sets were
designed based on the same Affymetrix probe-set and
differential expression of the gene assessed using MDA
MB231 and MCF7 samples. However, following PCR
analysis of MDA MB231 and MCF7 cDNA, results were
inconsistent. Similar to the results observed in the GEO
datasets, IL32 transcript levels were higher in MDA
MB231 compared to MCF7, but different sized amplicons
were generated depending on the cDNA preparation. The
decision was then made to consider primer-sets based on
different IL32 target regions. Search of the genomic data-
bases and the Affymetrix probe-set extension (i.e., “_s_at”)
indicate splice variants exist for IL32. In an attempt to
generate more consistent results, primer-sets correspond-
ing to different regions and variants were designed and
tested for reproducibility. Ultimately we selected a primer-






normal 190  +/-221
non-basal-like 290  +/-354
basal-like 1348  +/-1500
sample mean standard
deviation 
apocrine 130  +/-16
basal-like 254  +/-122
luminal 143  +/-27
sample mean standard
deviation 
luminal 4  +/-0.25
basal-like 180  +/-291
sample mean standard
deviation 
luminal 8  +-/4
basal 258  +/-385
Figure 1 Gene expression profiles demonstrating IL32 levels in the GEO datasets used in the study. The plot represents the normalized
IL32 gene expression levels observed for the Affymetrix 203826_s_at probeset in the (a) GDS2250 clinical samples (b) GDS1329 clinical samples
(c) GSE34211 cell lines and (d) GSE12777 cell line datasets. The dashed lines are used to group the particular sample types. The normalized gene
expression levels were averaged to demonstrate differences (i.e., mean) in IL32 levels between the various sample types. The mean and standard
deviations values were also determined (using Excel).
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same antigenic region as the antibody used for the protein
studies (Additional file 3: Figure S1). After the final
primer-set was chosen, IL32 levels in MCF7 and MDA
MB231 were again assessed (Figure 2a). The PCR ex-
periments were repeated more than 10 times using 3
different cDNA preparations and each time transcript
levels appeared higher in MBA MB231 compared to
MCF7. The experiment was also repeated using a com-
mercial source of MCF7 total RNA and two additional
endogenous control genes, all demonstrating the same
results. Also, we obtained cDNA generated from MDA
MB468 cell lines and examined the IL32 levels. Compared
to levels observed in GSE12777, IL32 in MDA MB468
appeared lower than levels observed in MCF7 (data
not shown). Consistent with PCR, western blot analysis
showed that IL32 protein levels were higher in MDA
MB231 compared to MCF7 (Figure 2b).
Assessment of IL32 protein expression in tissue microarray
containing clinically diagnosed patient samples
The same antibody used for western analysis was used
for IHC analysis of the TMAs. For our studies, CD31
signal intensity was used as the control to assess the
quality of the TMA tissue and the specificity of our anti-
body. After optimizing the antibody, if non-specific CD31
staining was observed the tissues were excluded from our
analyses. Ninety four total TMA cores demonstrated
CD31 signal intensities ≥ 3+, and subsequently included in
the IHC analyses. A summary of the IHC results are given
in Table 2. TMAs included TNBC, non-TNBC and non-
malignant breast samples. The samples included on theFigure 2 Analysis showing overexpression of IL32 gene
expression in MDA MB231 (TNBC) compared to MCF7 (receptor
positive). (a) PCR analysis of IL32 transcript in MCF7 compared to
MDA MB231. MRPL19 was used as the endogenous control gene
(b) Western analysis of IL32 protein in MCF7, MDA MB231, Positive
control protein and negative control. Actin gene was used as
endogenous control.TMAs contained clinical information and were defined
based on ER/PR/Her2 status. The most substantial
IL32 expression was observed in TNBC and non-
TNBC. Forty-two percent of the TNBC demonstrated
overexpression of IL32 while 25% of the non-TNBC
demonstrated overexpression. Negligible levels of IL32
were observed in normal and all but one benign tissue.
A list of the patient samples, including their clinical
information and individual IL32 staining intensities are
listed in Additional file 4: Table S3.
Examples of the IHC results are presented in Figure 3.
Figure 3a is an example of TNBC positive for IL32.
Figure 3c is an example of non-TNBC positive for IL32
expression. Figure 3e is an example of a non-TNBC nega-
tive for IL32 expression. Figure 3g shows positive IL32 ex-
pression in the sample previously diagnosed as an invasive
ductal carcinoma with residual normal/hyperplasia. IL32
expression in each of the samples appeared to be localized
to the cytoplasm of the epithelial cells. The corresponding
CD31 signal intensities for the samples noted above are
shown in Figures 3b, d, f and h.
Similar to the results observed in the GEO datasets,
IL32 gene expression was detected in several of the TNBC
and non-TNBC. Many of the TNBC and non-TNBC did
not display IL32 expression, and negligible levels were
observed in normal breast tissues. At this point, we have
not determined the implications of IL32 expression in the
malignant tissues. Future analyses will include analysis of
samples from a variety of different diagnoses, including
tumors with infiltrating inflammatory cell types.
Discussion
For this current study, we observed the IL32 gene differ-
entially expressed in basal-like and TNBC, performed
preliminary analysis of gene expression in particular cell
lines and tissue samples, and suggested it be examined
further for its role in breast cancers. IL32 is a cytokine,
and immune-related genes and cell types are proving to
be important tools in understanding the contribution of
the tumor’s microenvironment in breast cancer patho-
genesis. It is premature to suggest such a role for IL32,
but recent studies suggest that particular immune cells
and genes are clinically useful as prognostic or predictive
indicators for breast cancers. Rody et al. [23] identified a
Lymphocyte specific kinase (LCK; T-cell specific) cluster
of immune related genes that could separate the ESR-
negative patient population based on better or worse
prognosis. In a separate study, Denkert et al. [24] showed
that lymphocyte infiltration could be used to predict a
patients’ response to chemotherapeutic agents, where pa-
tients with previous infiltration responded more favorably
to therapy. Also, Gu-Trantien et al. [25] found that CD4+
follicular T-cells infiltrations in breast cancers could be
used to predict breast cancer survival. Unlike the studies
Table 2 Summary of IHC analysis of IL32 in patient samples (TMA)




Normal Normal Non triple negative 3/9 (1–2) ; 6/9 ND 0%
Fibroadenoma Benign Non triple negative 0/6 (0–1) 0%
Invasive ductal carcinoma with residual normal/hyperplasia Benign Non triple negative 1/1 (3) 100%
Atypical/Seveous atypical hyperplasia Hyperplasia Non triple negative 0/4 (0–1) 0%
Ductal carcinoma/Invasive ductal or lobular carcinoma Malignant Non triple negative 16/64 (3–4) ; 9 (1–2);
39/64 ND
25%
Invasive ductal carcinoma Malignant Triple negative 5/12 (3–4) ; 7/12 ND 42%
The pathology, nature and receptor status were determined by the TMA vendor. Ninety four total cores demonstrated CD31 signal intensity ≥ 3, and subsequently
included in the IHC analyses. The IL32 signal intensities were scored and the number of samples analyzed and their corresponding IL32 signal intensities listed.
The percent of samples with IL32 signal intensities ≥ 3+ were also given. ND = not detected. The signal intensity determined by 2 operators (AP and TO).
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of IL32 differential gene expression in breast samples.
A number of different validating experiments must be
completed if we are to establish the gene’s possible util-
ity. IL32 was discovered recently, so compared to other
genes mentioned in this report, relatively little information
exists demonstrating its role in clinical conditions.
IL32 has been shown to be involved in immune-related
defense mechanisms [26]. Considering the nature of the
gene, its activity has been established in inflammatory
diseases such as rheumatoid arthritis [27], rhinosinusi-
tis [28] chronic obstructive pulmonary disease [29] and
inflammatory bowel disease [30]. IL32 levels showed
positive correlations with tumor necrosis factor alpha,
ESR, C-reactive protein, replication factor, and Disease
Activity Score 28 genes in rheumatoid arthritis [31].
Studies related to mechanisms show that IL32 is induced
by NF-kappa-B [32] and in T cells and keratinocytes it
might play a role in apoptosis induced by T cell receptor
signaling and Interferon gamma γ [33,34]. Other studies
show the gene might regulate other cytokines [35] and
affect cell adhesion [36]. All of the mechanisms attributed
to IL32 could to some degree affect tumor progression.
The role of IL32 has also been examined in cancers,
supporting the myriad of data supporting a relationship
between inflammation and cancer. IL32 has been shown
to support tumor suppression in transgenic mice inoculated
with melanoma and colon cancer cells [37] and up-
regulated in lung adenocarcinomas [38] where it is consid-
ered a potential clinical target. In lung adenocarcinomas,
IL32 is highly expressed in both tumor cells and infiltrat-
ing leukocytes leading investigators to suggest that both
the lung tumor cells and tumor infiltrating leukocytes
are involved in tumor progression. IL32 is a cytokine
and cytokines have also been implicated in breast cancer
pathogenesis. Hartman et al. [39] show that blocking the
pro-inflammatory cytokine IL6 or associated pathwaysmight be a useful therapeutic strategy for TNBC support-
ing a role of cytokines in the tumorigenic process. Other
studies show high levels of IL6 in serum of breast cancers
appear to be related to poor prognosis [40], possibly
involved in epithelial-to-mesenchymal transition [41].
Barclay et al. [42] showed that overexpression of Suppres-
sor of Cytokine Signaling 3 molecules (SOCS3) suppresses
STAT3 expression, which then decreases cell proliferation
of breast cancer cells. These data suggest SOCS3 might
have a role in tumor progression.
We report IL32 levels in breast cancer cells and clinical
samples in which the receptor status and diagnosis has
been previously determined. Our study is meant to be a
preliminary analysis of IL32, demonstrating its expression
in breast tissues. We observed IL32 overexpression in se-
lect TNBC, non-TNBC, and a hyperplastic breast sample
compared to normal breast tissues, but we have not deter-
mined the implications of IL32 expression. A main object-
ive of this study remains identification of genes that
distinguish TNBC so they might be considered for future
studies. To better understand the role of IL32 in breast
tissues, the individual splice variants and coding proteins
must be examined, current results must be validated using
samples with more detailed clinical information, knock-
down studies should be performed, and signaling and
receptor proteins should be identified to determine the
contribution of the gene to tumor pathogenesis. None
of these experiments have been performed. To address
one of the concerns noted above, we examined three
different genomic regions associated with IL32 transcript
variants and tested the primer-sets before we selected our
final primer-set, but not to the extent the process was
optimized.
As we were processing our data, we discovered a study
by Park et al. [43] describing IL32 expression in MDA
MB231 and MCF7. The investigators found that Interleukin





Figure 3 IHC analysis of IL32 levels in TMA. CD31 and IL32 protein expression was determined in various types of breast tissues. TNBC
demonstrating (a) positive IL32 expression and (b) CD31 control expression. Non-TNBC demonstrating (c) positive IL32 expression and (d) CD31
control expression. Non-TNBC demonstrating (e) negative IL32 expression and (f) CD31 control expression. Invasive ductal or lobular carcinoma
demonstrating (g) positive IL32 expression and (h) CD31 control expression. Bar = 50uM.
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http://www.biomedcentral.com/1756-0500/7/501cells and defined the mechanism as related to vascular
endothelial growth factor- signal transducer and activa-
tor of transcription 3 (VEGF-STAT3) signaling. These
data would suggest both cell lines have receptor mole-
cules available for stimulation by IL32. Our experimen-
tal results repeatedly show that under normal growthconditions higher levels of IL32 in MDA MB231, when
transcript levels detecting several variants are assessed.
Our studies allowed for detection of a cocktail of IL32
transcript variants (including IL32 β); so the targets
examined and the focus of their and our studies is very
different.
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http://www.biomedcentral.com/1756-0500/7/501Not all of the TNBC examined in our study were
positive for IL32; some of the TMA cores were negative
(even though CD31 activity was detected). In addition,
a smaller portion of the non-TNBC tissues showed evi-
dence of IL32 expression, while many of the normal tis-
sues showed negligible levels. Related to the GSE34211
datasets, only 7 of the 18 triple negative cell lines showed
substantial levels of IL32 expression compared to luminal
subtype, while the MCF10A and MCF12A cell lines
expressed IL32 levels comparable to that observed in
the luminal subtype. Interestingly, five of the same cell
lines (i.e., HCC1569, HCC1143, MDA MB436, Cal851
and Hs578T) demonstrated IL32 overexpression in both
GSE34211 and GSE12777 datasets. Considering these
data altogether, IL32 demonstrates a particular pattern
of gene expression worthy of further consideration.
Conclusion
We are aware that a limited number of datasets and
samples are analyzed and processed for the current
experiments. However as a preliminary study taking
into account our results combined with information
gathered from the GEO public datasets, the data suggest
IL32 is differentially expressed in breast samples. It is
important to both repeat and expand our studies and
determine the implications of the IL32 gene expression
pattern, using larger numbers of patient samples with
extensive accompanying clinical data.
Additional files
Additional file 1: Table S1. Analysis of IL32 splice variants and
comparison to current PCR primer-set. Table lists the RefSeq splice
variants for the IL32 gene [16,17]. Yes/no refers to whether or not our
IL32 primer-set recognizes the particular splice variant. The numbers
in parenthesis represent the amino acids associated with the protein
that differ from what is considered the canonical IL32 sequence.
Additional file 2: Table S2. List of Ensembl protein and transcript
identifications for the sequences used to generate the commercial IL32
antibody. The table lists the protein and transcripts that correspond to
the antigenic regions of the commercial IL32 antibody [15,21]. The final
column identifies the proteins/transcripts that are also recognized by the
primers used for detecting our 207 bp PCR amplicon. Alignment based
on Multialign™.
Additional file 3: Figure S1. Ensembl transcripts and NCBI IL32 RefSeq
splice variant comparisons to our 207 base amplicon. The 207 bp PCR
amplicon is aligned with the Ensembl transcripts that match the epitope
for the IL32 antibody and the IL32 RefSeq splice variants. The dashed
arrows show the start to stop of the 207 bp amplicon nucleotides
(approximately 576–783). Arrow designates the amplicon position above
the consensus sequences. Red color shows concordance across all
samples; blue color shows partial concordance. The PCR amplicon aligns
with all but two RefSeq variants and three transcripts matching the
protein epitope (circles).
Additional file 4: Table S3. Summary of clinical samples on TMA. All of
the designations were assigned by the vendor. The pathology, nature, stage,
ER/PR/Her2 information was supplied by Pantomics Inc. ER/PR/Her2 analyses
were performed by the vendor using IHC technique; signal intensities were
also determined by the vendor. Clinical samples negative for ER/PR/Her2 aredesignated TNBC and highlighted in yellow. The CD31 and IL32 signal
intensities were scored by 2 operators (AP and TO). The samples labeled
with “**” were used for IHC figure 2.
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